According to Reuters a fall in the Japanese share was witnessed. This was mainly due to concerns on the delay of the distribution of the corona virus vaccine and anxiety of earnings ahead of profit-taking in stocks that are sensitive to the economic cycle.
The Nikkei 225 Index fell 0.65% to 28,635.54 by 0136 GMT, with consumer cyclicals, energy and materials makers leading the decline. The broader Topix fell 0.52% to 1,852.34.
Investor reaction is balancing on the fact that Japan has not commenced on the vaccinations up to now, while the US has labored to speed up vaccinations and European countries are confronted with delays from the suppliers.
Additional worry lies about the supply of the vaccines as it is reported that, Merck & Co Inc. has terminated the production of its COVI-19 vaccines.
A Federal Reserve Meeting which ended last Wednesday is provoking investors to take profits in spite of the Japanese share jumping to a 30- year high last week while it was also a busy revenue calendar in the US and Japan during the week under purview.
“There are renewed concerns that the coronavirus will be with us longer than anticipated, which explains the decline in cyclical stocks and gains in defensive shares,” said Norihiro Fujito, chief investment strategist at Mitsubishi UFJ Morgan Stanley Securities.
Several Bank of Japan policymakers called for more flexible purchases of exchange-traded funds, which may emerge as another negative factor for equities when the central bank reviews its policies in March, according to some analysts.
Top underperformers on the Topix 30 were Daikin Industries Ltd, down 2.38%, followed by Toyota Motor Corp losing 2.07%.
Top gainers were Takeda Pharmaceutical Co Ltd, up 1.99%, followed by Nidec Corp rising 1.96.
There were 57 advancers on the Nikkei index against 162 decliners. The volume of shares traded on the Tokyo Stock Exchange’s main board was 0.4 billion, compared to the average of 1.12 billion in the past 30 days.
